Table 4.
Subsequent systemic treatments in the A + T and TKI alone groups.
| Study | A + T group | TKI alone group |
|---|---|---|
| Rates of total subsequent systemic treatments (n/N) (%) | ||
| JO25567 [12] | 64/75 (85.3%) | 65/77 (84.4%) |
| Stinchcombe [20] | 23/43 (53.5%) | 21/45 (46.7%) |
| NEJ026 [13] | 85/112 (75.9%) | 93/112 (83%) |
| RELAY [15] | 120/224 (53.6%) | 156/225 (69.3%) |
| Pooled rates | 67.9% (95% CI: 63.8–72%) | 75.3% (95% CI: 71.4–79.1%) |
| Pooled RR | 0.881 (95% CI: 0.808–0.960), P = 0.002 | |
| Rates of subsequent osimertinib treatment (n/N) (%) | ||
| Stinchcombe [20] | 10/23 (43.5%) | 13/21 (61.9%) |
| NEJ026 [13] | 29/85 (34.1%) | 28/93 (30.1%) |
| RELAY [15] | 18/120 (15%) | 35/156 (22.4%) |
| Pooled rates | 22% (95% CI: 16.8–27.2%) | 27.2% (95% CI: 22.1–32.4%) |
| Pooled RR | 0.858 (95% CI: 0.642–1.146), P = 0.299 | |
| Rates of subsequent chemotherapy (n/N) (%) | ||
| JO25567 [12] | 26/64 (40.6%) | 20/65 (30.8%) |
| NEJ026 [13] | 44/85 (51.8%) | 57/93 (61.3%) |
| RELAY [15] | 27/120 (22.5%) | 40/156 (25.6%) |
| Pooled rates | 34.8% (95% CI: 29.4–40.3%) | 35.9% (95% CI: 30.8–40.9%) |
| Pooled RR | 0.969 (95% CI: 0.79–1.189), P = 0.766 | |
TKI: tyrosine kinase inhibitor; A + T: angiogenic inhibitors combined with TKI.